Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer

Cancer Research

Volumn 56, Issue 6, 1996, Pages 1244-1249

  Miyake, Masayuki ^a   Nakano, Keiji ^a   Itoi, Shin Ichi ^a   Koh, Takashi ^b   Taki, Toshihiko ^a  

^a Kitano Hospital   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD9 ANTIGEN;

ADULT; ARTICLE; BREAST CANCER; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EXAMINATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS;

ANTIGENS, CD; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 0029876559     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Early Breast Cancer Trialists' Collaborative Group. Effect of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women. N. Engl. J. Med., 319. 1681-1692, 1988.
2. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet, 339 1-15, 71-85, 1992.
3. Muss, H. B., Thor, A. D., Berry, D. A., Kute, T., Liu, E. T., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C., Barcos, M., and Henderson, I. C. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl. J. Med., 330. 1260-1266, 1994.
4. Pavelic, Z. P , Pavelic, L , Lower, E. E , Gapany, M , Gapany, S., Baker, E A., and Preisler, H D c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma. Cancer Res , 52: 2597-2602, 1992.
5. McCann, A. H., Dervan, P. A , O'Regan, M , Codd, M. B., Gullick, W. J., Tobin, B. M. J., and Carney, D N Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res., 51: 3296-3303, 1991.
6. Callahan, R , Cropp, C. S., Merlo, G. R., Liscia, D. S., Cappa, A. P M , and Lidereau, R. Somatic mutations and human breast cancer: a status report. Cancer. 69(Suppl.): 1582-1588, 1992.
7. Allred, D. C., Clark, G M., Elledge, R , Fuqua, A. W., Brown, R. W., Chamness, G C , Osborne, C. K., and McGuire, W. L. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-neaative breast cancer. J. Natl Cancer Inst., 85: 200-206, 1993.
8. Barnes, R., Masood, S., Barker, E., Rosengard, A. M., Coggin, D L., Crowell, T., King, C. R., Porter-Jordan, K., Wargotz, E. S., Liotta, L. A., and Steeg, P S. Low nm23 protein expression in infiltrating ductal breast carcinomas correlates with reduced patient survival. Am. J. Pathol., 139: 245-250, 1991.
9. Hennessy, C., Henry, J. A. May, F. E. B , Westley, B. R. Angus, B., and Lennard, T. W. J. Expression of the antimetastatic gene nm23 in human breast cancer: an association with good prognosis J Natl. Cancer Inst., 83: 281-285, 1991.
10. Miyake, M., Koyama, M., Seno, M., and Ikeyama, S Identification of the motility-related protein (MRP-1), recognized by monoclonal antibody M31-15, which inhibits cell motility. J. Exp. Med., 174. 1347-1354, 1991.
11. Boucheix, C., Benoit, P., Frachet, P , Billard, M , Worthington, R. E., Gagnon, J., and Uzan, G. Molecular cloning of the CD9 antigen. J. Biol. Chem., 266. 117-122, 1991.
12. Ikeyama, S., Koyama, M., Yamaoko, M., Sasada, R , and Miyake, M. Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA. J. Exp. Med., 177: 1231-1237, 1993.
13. Miyake, M., Nakano, K., Ieki, Y., Adachi, M., Huang, C. Itoi, S , Koh, T., and Taki, T. Motility related protein-1 (MRP-1/CD9) expression: inverse correlation with metastases in breast cancer Cancer Res., 55. 4127-4131, 1995.
14. Higashiyama, M., Taki, T , Ieki, Y., Adachi, M., Huang, C , Koh, T., Kodama, K. Doi, O , and Miyake, M. Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer. Cancer Res., 55: 6040-6044, 1995.
15. Hermanek, P., and Sobin, L. H (eds.) TNM Classification of Malignant Tumours, 4th ed., pp. 103-109. Berlin: Springer-Verlag, 1987.
16. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227: 680-685, 1970.
17. Towbin, H., Staehelin, T., and Gordon, J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl Acad. Sci. USA, 76: 4350-4354, 1979.
18. Kaplan, E L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am Stat. Assoc., 53: 457-481, 1958.
19. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep , 50: 163-170, 1966.
20. Cox, D. R. Regression models and life-tables. J. R. Stat. Soc. B., 34: 187-220, 1972.
21. Miyake, M., and Hakomon, S A specific cell surface glycoconjugate controlling cell motility evidence by functional monoclonal antibodies that inhibit cell motility and tumor cell metastasis Biochemistry, 30: 3328-3334, 1991.
22. Kohn, E. C., and Liotta, L. A. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res., 55: 1856-1862, 1995.
23. Masellis-Smith, A., and Shaw, A. R. E CD9-regulated adhesion: anti-CD9 monoclonal antibody induce pre-B cell adhesion to bone marrow fibroblasts through de novo recognition of fibronectin. J. Immunol., 152: 2767-2777, 1994
24. Forsyth, K. D. Anti-CD9 antibodies augment neutrophil adherence to endothelium. Immunology, 72: 292-296, 1991.
25. Horejsi, V., and Vlcek, C. Novel structurally distinct family of leukocyte surface glycoproteins including CD9, CD37, CD53 and CD53. FEBS Lett., 288: 1-4, 1991.
26. Wright, M D., and Tomlinson, M. G. The ins and outs of the transmembrane 4 superfamily. Immunol. Today. 15: 588-594, 1994
27. Hotta, H., Ross, A. H , Huebner, K., Isobe, M , Wendeborn, S., Chao, M V., Ricciardi, R. P., Tsujimoto, Y., Croce, C. M., and Koprowski, H. Molecular cloning and characterization of an antigen associated with early stages of melanoma tumor progression. Cancer Res , 48: 2955-2962, 1988.
28. Dong, J-T., Lamb, P. W., Rinker-Schaeffer, C W., Vukanovic, J., Ichikawa, T., Isaacs, J. T., and Barrett, J C. KAI-1, a metastatis suppressor gene for prostate cancer on human chromosome 11p11.2 Science (Washington DC), 268: 884-886, 1995.
29. Gaugitsch, H W., Hofer, E., Huber, N. E., Schnabal, E., and Baumruker, T. A new superfamily of lymphoid and melanoma cell proteins with extensive homology to Schistosoma mansoni antigen Sm23. Eur J. Immunol., 21: 377-383, 1991.
30. Imai, T., Fukudome, K., Takagi, S., Nagira, M., Furuse, M., Fukuhara, N., Nishimura, M , Hinuma, Y., and Yoshie, O. C33 antigen recognized by monoclonal antibodies inhibitory to human T cell leukemia virus type 1-induced syncytium formation is a member of a new family of transmembrane proteins including CD9, CD37, CD53, and CD63. J. Immunol., 149: 2879-2886, 1992.